Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Entero Therapeutics, Inc.
Entero Therapeutics, Inc. News
Entero Therapeutics, Inc. Quantitative Score
About Entero Therapeutics, Inc.
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Entero Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Entero Therapeutics, Inc. Financials
Table Compare
Compare ENTO metrics with: | |||
|---|---|---|---|
Earnings & Growth | ENTO | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ENTO | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ENTO | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ENTO | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Entero Therapeutics, Inc. Income
Entero Therapeutics, Inc. Balance Sheet
Entero Therapeutics, Inc. Cash Flow
Entero Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Entero Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Ms. Anna Skowron | Chief Financial Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Ms. Anna Skowron | Chief Financial Officer | Female | 1987 | -- |
Entero Therapeutics, Inc. Insider Trades
| Date | 3 Feb |
| Name | Uppal Manpreet |
| Role | Director |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 5 Feb |
| Name | Corbett Eric |
| Role | Director |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 3 Feb |
| Name | Paolone Richard |
| Role | Interim CEO |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 6 Jan |
| Name | Romano Sarah |
| Role | Chief Financial Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 727 |
| Date | 9 Oct |
| Name | Romano Sarah |
| Role | Chief Financial Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 476 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 3 Feb | Uppal Manpreet | Director | Disposed | 0 | |
| 5 Feb | Corbett Eric | Director | Disposed | 0 | |
| 3 Feb | Paolone Richard | Interim CEO | Disposed | 0 | |
| 6 Jan | Romano Sarah | Chief Financial Officer | Disposed | S-Sale | 727 |
| 9 Oct | Romano Sarah | Chief Financial Officer | Disposed | S-Sale | 476 |